What Will Biosimilar Labeling Look Like? Stakeholders Await FDA Guidance, Approvals
Executive Summary
Unknowns include whether labeling will include reference product’s clinical data, and how absence of data for particular indications or populations will be handled; labeling decisions for 351(k) approvals will have important ramifications for advertising and promotion of both the biosimilar and reference product.